Literature DB >> 23759454

Current status of ketamine and related compounds for depression.

Daniel C Mathews1, Carlos A Zarate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23759454      PMCID： PMC3785314          DOI： 10.4088/JCP.13ac08382

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  40 in total

1.  On the safety and benefits of repeated intravenous injections of ketamine for depression.

Authors:  Pierre Blier; Daniel Zigman; Jean Blier
Journal:  Biol Psychiatry       Date:  2012-04-12       Impact factor: 13.382

Review 2.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 3.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

4.  A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Authors:  Lobna Ibrahim; Nancy Diaz Granados; Libby Jolkovsky; Nancy Brutsche; David A Luckenbaugh; W Joseph Herring; William Z Potter; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

5.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

6.  Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity.

Authors:  Yongqing Lai; Song Wu; Liangchao Ni; Zebo Chen; Xianxin Li; Shangqi Yang; Yaoting Gui; Zhichen Guan; Zhiming Cai; Jiongxian Ye
Journal:  Urol Int       Date:  2012-06-16       Impact factor: 2.089

7.  Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

Authors:  Michael H Bloch; Suzanne Wasylink; Angeli Landeros-Weisenberger; Kaitlyn E Panza; Eileen Billingslea; James F Leckman; John H Krystal; Zubin Bhagwagar; Gerard Sanacora; Christopher Pittenger
Journal:  Biol Psychiatry       Date:  2012-07-10       Impact factor: 13.382

8.  Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.

Authors:  Carlos A Zarate; Nancy Brutsche; Gonzalo Laje; David A Luckenbaugh; Swarajya L Vattem Venkata; Anuradha Ramamoorthy; Ruin Moaddel; Irving W Wainer
Journal:  Biol Psychiatry       Date:  2012-04-18       Impact factor: 13.382

9.  Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Authors:  Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte
Journal:  Int J Geriatr Psychiatry       Date:  2011-12-16       Impact factor: 3.485

Review 10.  Synaptic mechanisms underlying rapid antidepressant action of ketamine.

Authors:  Ege T Kavalali; Lisa M Monteggia
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112
View more
  10 in total

Review 1.  Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.

Authors:  B G Bunney; J Z Li; D M Walsh; R Stein; M P Vawter; P Cartagena; J D Barchas; A F Schatzberg; R M Myers; S J Watson; H Akil; W E Bunney
Journal:  Mol Psychiatry       Date:  2014-11-04       Impact factor: 15.992

Review 2.  Stress and VTA synapses: implications for addiction and depression.

Authors:  Abigail M Polter; Julie A Kauer
Journal:  Eur J Neurosci       Date:  2014-04       Impact factor: 3.386

3.  A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex.

Authors:  Ricardo Orozco-Solis; Emilie Montellier; Lorena Aguilar-Arnal; Shogo Sato; Marquis P Vawter; Blynn G Bunney; William E Bunney; Paolo Sassone-Corsi
Journal:  Biol Psychiatry       Date:  2017-03-01       Impact factor: 13.382

Review 4.  Inflammation: a mechanism of depression?

Authors:  Qiu-Qin Han; Jin Yu
Journal:  Neurosci Bull       Date:  2014-05-16       Impact factor: 5.203

5.  Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy.

Authors:  Sarah A Stuart; Paul Butler; Marcus R Munafò; David J Nutt; Emma S J Robinson
Journal:  Neuropsychopharmacology       Date:  2015-03-05       Impact factor: 7.853

Review 6.  Pharmacological approaches to the challenge of treatment-resistant depression.

Authors:  Dawn F Ionescu; Jerrold F Rosenbaum; Jonathan E Alpert
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

7.  Rapid Resolution of Grief with IV Infusion of Ketamine: A Unique Phenomenological Experience.

Authors:  Mahesh Ramanna Gowda; Preethi Srinivasa; Prabha S Kumbar; Vinay Hosagavi Ramalingaiah; Chandrashekar Muthyalappa; Sumit Durgoji
Journal:  Indian J Psychol Med       Date:  2016 Jan-Feb

8.  Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus.

Authors:  Silvia Poggini; Maria Teresa Golia; Silvia Alboni; Giampaolo Milior; Livio Pepè Sciarria; Aurelia Viglione; Gloria Matte Bon; Nicoletta Brunello; Stefano Puglisi-Allegra; Cristina Limatola; Laura Maggi; Igor Branchi
Journal:  Neural Plast       Date:  2019-01-21       Impact factor: 3.599

9.  Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series.

Authors:  Bethany Tellor; Nicole Shin; Thomas J Graetz; Michael S Avidan
Journal:  F1000Res       Date:  2015-01-16

10.  Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol.

Authors:  Ben J A Palanca; Hannah R Maybrier; Angela M Mickle; Nuri B Farber; R Edward Hogan; Emma R Trammel; J Wylie Spencer; Donald D Bohnenkamp; Troy S Wildes; ShiNung Ching; Eric Lenze; Mathias Basner; Max B Kelz; Michael S Avidan
Journal:  Front Psychiatry       Date:  2018-05-14       Impact factor: 4.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.